

GLAXOSMITHKLINE PLC

Form 6-K

March 12, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 12 March 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
b) Position/status Chief Executive Officer

- c) Initial notification/
amendment Initial notification
Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each
('Ordinary Shares')

- b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares
under the Company's Share
Reward Plan.

- c) Price(s) and volume(s) Price(s) Volume(s)
£13.4317 10 (partnership shares)
£13.4317 10 (matching shares)

Aggregated information

- d) Aggregated volume 20 Ordinary Shares

Price £13.4317

- e) Date of the transaction 2018-03-09

- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
b) Position/status

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

President, Global Manufacturing &
Supply

- c) Initial notification/
amendment Initial notification
Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
3. where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each
(‘Ordinary Shares’)

ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares
under the Company's Share Reward
Plan.

- c) Price(s) and volume(s) Price(s) Volume(s)
£13.4317 10 (partnership shares)
£13.4317 10 (matching shares)

Aggregated information

- d) Aggregated volume 20 Ordinary Shares

Price £13.4317

- e) Date of the transaction 2018-03-09

- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S Dingemans
b) Position/status Chief Financial Officer

- c) Initial notification/
amendment Initial notification
Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
3. where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £13.4317 10 (partnership shares) £13.4317 10 (matching shares)
Aggregated information	
d) Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr N Hiron
 - b) Position/status SVP, Global Ethics & Compliance
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £13.4317 10 (partnership shares) £13.4317 10 (matching shares)
d) Aggregated information	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr L Miels
 - b) Position/status President, Global Pharmaceuticals
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')						
	ISIN: GB0009252882						
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.						
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£13.4317</td> <td>10 (partnership shares)</td> </tr> <tr> <td>£13.4317</td> <td>10 (matching shares)</td> </tr> </table>	Price(s)	Volume(s)	£13.4317	10 (partnership shares)	£13.4317	10 (matching shares)
Price(s)	Volume(s)						
£13.4317	10 (partnership shares)						
£13.4317	10 (matching shares)						

Aggregated information

d) Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer

- c) Initial notification/
amendment Initial notification
Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each
(‘Ordinary Shares’)
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares
under the Company's Share Reward
Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
£13.4317 10 (partnership shares)
£13.4317 10 (matching shares)
- Aggregated information
- d) Aggregated volume 20 Ordinary Shares
Price £13.4317
- e) Date of the transaction 2018-03-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them (‘PCA’)
a) Name Ms C Thomas
b) Position/status SVP, Human Resources
c) Initial notification/
amendment Initial notification
Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each
(‘Ordinary Shares’)

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
£13.4317 10 (partnership shares)
£13.4317 10 (matching shares)

Aggregated information

d) Aggregated volume 20 Ordinary Shares

Price £13.4317

e) Date of the transaction 2018-03-09

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status President, Global Affairs

c) Initial notification/
amendment Initial notification

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
£13.4317 9 (partnership shares)
£13.4317 9 (matching shares)

d) Aggregated information

Aggregated volume 18 Ordinary Shares

Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr P J T Vallance
b) Position/status	President, R&D
c) Initial notification/ amendment	Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)	Price(s) Volume(s)
	£13.4317 9 (partnership shares)
	£13.4317 9 (matching shares)

Aggregated information

d) Aggregated volume	18 Ordinary Shares
----------------------	--------------------

Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mrs V A Whyte
b) Position/status	Company Secretary
c) Initial notification/	Initial notification

amendment

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each
(‘Ordinary Shares’)

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction

Acquisition of Ordinary Shares
under the Company's Share Reward
Plan.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£13.4317	10 (partnership shares)
£13.4317	10 (matching shares)

Aggregated information

d) Aggregated volume

20 Ordinary Shares

Price

£13.4317

e) Date of the transaction

2018-03-09

f) Place of the transaction

London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: March 12, 2018

By: VICTORIA WHYTE-----

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc